FMP
Enter
API Tools
Extras
Satsuma Pharmaceuticals, Inc.
STSA
NASDAQ
Inactive Equity
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
1.1 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
